IBX Secures Firm Commitments for $3.75m for Clinical Trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The company plans to use the funds for trial activation, drug manufacturing, and collaborations with MRI experts. The announcement includes details about the placement structure and the expected timeline for the trial and share allotment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
- Imagion Biosystems Receives IND Clearance from US FDA
- Appendix 4C and Quarterly Activities Report - March 2026
- FY25 Appendix 4E and Annual Report
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
Later from Imagion Biosystems
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- Appendix 4C and Quarterly Activities Report - June 2026
- IBX Phase 2 Clinical Trial Update
- MagSense Nanoparticle Manufacturing Update
- Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems